Hesperidin RCT in MS
A Randomized, Placebo-Controlled Trial of Hesperidin for Fatigue,Mood, and Cognitive Function in Multiple Sclerosis
Swansea University
60 participants
Jan 7, 2026
INTERVENTIONAL
Conditions
Summary
This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress. Participants will be randomly assigned to receive either 500mg of Hesperidin or a matching placebo daily for 12 weeks. The primary outcome is fatigue, with secondary outcomes including cognitive performance and mood. The trial seeks to determine if this dietary intervention offers symptom-alleviating benefits.
Eligibility
Inclusion Criteria1
- Diagnosis of Multiple Sclerosis, Aged 18 years or older.
Exclusion Criteria1
- Known food allergies, intolerances, or significant gastrointestinal (GI) problems, Participants under the age of 18 years.
Interventions
500 mg/day Hesperidin capsules for 12 weeks
Matching maltodextrin capsules for 12 weeks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07452562